Kalaris Therapeutics announces positive initial data from Phase 1a trial of TH103 in neovascular AMD patients.
TH103 demonstrates significant improvements in vision and retinal anatomy with potential for extended durability.
The drug shows promising efficacy and safety profile, supporting further dose escalation and ongoing trials.
Promising Results
TH103 shows mean 10-letter gain in visual acuity and rapid anatomic improvement at Month 1.
Enhanced Potency
TH103 engineered for extended intraocular retention with enhanced VEGF inhibition.
Safety Profile
TH103 generally well tolerated with no significant adverse events observed.
Extended Durability
31% of patients received no additional anti-VEGF treatment during six-month follow-up after single TH103 injection.
- TH103's engineered properties lead to 27 to 51-fold lower plasma Cmax compared to current anti-VEGF agents, indicating increased intraocular retention.
- Initial data suggests potential for extended treatment durability with promising clinical activity and safety profile.
The positive initial Phase 1a data for TH103 demonstrate its potential as an effective treatment option for neovascular AMD, paving the way for further development and clinical trials.